STUDY DESIGN: In vitro experiment using human intervertebral disc (IVD) cells and adenovirus-therapeutic gene constructs. OBJECTIVE: To examine the biologic effect of "cocktail" therapeutic gene transfer to human IVD cells in three-dimensional cultures. SUMMARY OF BACKGROUND DATA: Gene therapy is regarded as a potential option for the treatment of degenerative disc disease. Although various anabolic genes have previously been introduced for this purpose, cocktail gene transfer of anabolic genes to IVD cells has never been attempted. METHODS: Human IVDs were harvested during surgical disc procedures and cultured. We prepared recombinant adenovirus constructs bearing the TGF-beta1 gene (Ad/TGF-beta1), the IGF-1 gene (Ad/IGF-1), and the BMP-2 gene (Ad/BMP-2). Transgene expression was detected by luciferase assays, enzyme linked immunosorbent assays, and Western blot analysis. Newly synthesized proteoglycan was measured by S-sulfate incorporation on Sephadex G-25 M in PD 10 columns. Human IVD cells were transduced by single, double, and triple combination of Ad/TGF-beta1, Ad/IGF-1, Ad/BMP-2 with an MOI of 75, then cultured three-dimensionally in alginate beads. RESULTS: Transgene expression was detected at 18 hours after viral transduction. IVD cultures with Ad/TGF-beta1, Ad/IGF-1, Ad/BMP-2 (MOI of 75) showed 2.9, 1.8, and 1.9 fold increases, respectively, in proteoglycan synthesis compared to control. Human IVD cultures with double gene combination (MOI of 75) showed 3.2 to 3.9 fold increases of proteoglycan synthesis. Lastly, Human IVD cultures with triple gene combination (TGF-beta1+IGF-1+BMP-2 genes with an MOI of 75) transfer demonstrated 4.7 fold increase in proteoglycan synthesis compared control. CONCLUSION: Combination or "cocktail" gene therapy offers a promising mechanism for maximizing matrixsynthesis with low dose of adenoviral mixtures, circumventing systemic, local toxic effect, and immune response.
STUDY DESIGN: In vitro experiment using human intervertebral disc (IVD) cells and adenovirus-therapeutic gene constructs. OBJECTIVE: To examine the biologic effect of "cocktail" therapeutic gene transfer to human IVD cells in three-dimensional cultures. SUMMARY OF BACKGROUND DATA: Gene therapy is regarded as a potential option for the treatment of degenerative disc disease. Although various anabolic genes have previously been introduced for this purpose, cocktail gene transfer of anabolic genes to IVD cells has never been attempted. METHODS:Human IVDs were harvested during surgical disc procedures and cultured. We prepared recombinant adenovirus constructs bearing the TGF-beta1 gene (Ad/TGF-beta1), the IGF-1 gene (Ad/IGF-1), and the BMP-2 gene (Ad/BMP-2). Transgene expression was detected by luciferase assays, enzyme linked immunosorbent assays, and Western blot analysis. Newly synthesized proteoglycan was measured by S-sulfate incorporation on Sephadex G-25 M in PD 10 columns. Human IVD cells were transduced by single, double, and triple combination of Ad/TGF-beta1, Ad/IGF-1, Ad/BMP-2 with an MOI of 75, then cultured three-dimensionally in alginate beads. RESULTS: Transgene expression was detected at 18 hours after viral transduction. IVD cultures with Ad/TGF-beta1, Ad/IGF-1, Ad/BMP-2 (MOI of 75) showed 2.9, 1.8, and 1.9 fold increases, respectively, in proteoglycan synthesis compared to control. Human IVD cultures with double gene combination (MOI of 75) showed 3.2 to 3.9 fold increases of proteoglycan synthesis. Lastly, Human IVD cultures with triple gene combination (TGF-beta1+IGF-1+BMP-2 genes with an MOI of 75) transfer demonstrated 4.7 fold increase in proteoglycan synthesis compared control. CONCLUSION: Combination or "cocktail" gene therapy offers a promising mechanism for maximizing matrixsynthesis with low dose of adenoviral mixtures, circumventing systemic, local toxic effect, and immune response.
Authors: K Nishida; J D Kang; L G Gilbertson; S H Moon; J K Suh; M T Vogt; P D Robbins; C H Evans Journal: Spine (Phila Pa 1976) Date: 1999-12-01 Impact factor: 3.468
Authors: G Mazzolini; I Narvaiza; A Pérez-Diez; M Rodriguez-Calvillo; C Qian; B Sangro; J Ruiz; J Prieto; I Melero Journal: Gene Ther Date: 2001-02 Impact factor: 5.250
Authors: J Nemunaitis; C Cunningham; A Buchanan; A Blackburn; G Edelman; P Maples; G Netto; A Tong; B Randlev; S Olson; D Kirn Journal: Gene Ther Date: 2001-05 Impact factor: 5.250
Authors: Jay N Lozier; Gyorgy Csako; Traci H Mondoro; D M Krizek; Mark E Metzger; Rene Costello; Jaroslav G Vostal; M E Rick; Robert E Donahue; Richard A Morgan Journal: Hum Gene Ther Date: 2002-01-01 Impact factor: 5.695
Authors: S H Moon; L G Gilbertson; K Nishida; M Knaub; T Muzzonigro; P D Robbins; C H Evans; J D Kang Journal: Spine (Phila Pa 1976) Date: 2000-10-15 Impact factor: 3.468
Authors: Hak-Sun Kim; Manjula Viggeswarapu; Scott D Boden; Yunshan Liu; Gregory A Hair; John Louis-Ugbo; Hideki Murakami; Akihito Minamide; Daniel Y Suh; Louisa Titus Journal: Spine (Phila Pa 1976) Date: 2003-02-01 Impact factor: 3.468
Authors: James Dowdell; Mark Erwin; Theodoe Choma; Alexander Vaccaro; James Iatridis; Samuel K Cho Journal: Neurosurgery Date: 2017-03-01 Impact factor: 4.654
Authors: Khoi D Than; Shayan U Rahman; Lin Wang; Adam Khan; Kwaku A Kyere; Tracey T Than; Yoshinari Miyata; Yoon-Shin Park; Frank La Marca; Hyungjin M Kim; Huina Zhang; Paul Park; Chia-Ying Lin Journal: Spine J Date: 2013-12-01 Impact factor: 4.166
Authors: Elias S Vasiliadis; Spyros G Pneumaticos; Demitrios S Evangelopoulos; Athanasios G Papavassiliou Journal: Mol Med Date: 2014-09-18 Impact factor: 6.354